The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

Childhood obesity continues to be a growing problem in out country. So, should the government regulate food advertising like it did with cigarettes?

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

That locked up the obesity drug. But after 9 Meters started ... Wegovy, for example, "doesn't really work" — at least to the Food and Drug Administration standard of weight loss of 5% or more ...

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The U.S. Food and Drug Administration (FDA ... Will Medicare end Novo Nordisk's obesity drug boom? It's not surprising that CMS chose Ozempic, Wegovy, and Rybelsus for Medicare drug price ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...